Products will initially be used for research purposes.

Proteome Sciences will develop assays to measure its brain-damage biomarkers on Axela’s dotLab™ System. The markers will be incorporated into Axela’s panelPlus™ Biomarker Menu for clinical research and eventual diagnostic applications.

Under the terms of the license, Axela will provide a dotLab system and consumable reagents and will have the option to developed assays for research and diagnostic uses. panelPlus Sensors provide real-time, user-configurable approach to multiplexing and greatly simplify validation of both clinical utility and analytical performance, remarks Rocky Ganske, Axela president and CEO. 

Proteome’s patents reportedly cover conditions like stroke, subarachnoid haemorrhage, traumatic brain injury, Parkinson’s, ALS, and Alzheimer’s disease. These biomarkers were identified in collaboration with the Biomedical Proteomics Research Group (BPRG) at the University of Geneva.

Besides its in-house research neurological and neurodegenerative conditions, Proteome Sciences also acts as a biomarker CRO. It provides protein biomarker discovery, validation, and assay development services. The company’s MS Biomarker Assay (MBA) system uses its isobaric Tandem Mass Tags (TMT) and reference materials combined with isotope dilution mass spectrometry.

Related News

IBA Pads Assay Development Services with Acquisition of Axela Technology (Mar. 19, 2009)
Proteome Sciences Awarded European Patent for Stroke Diagnostic Methods (Jan. 15, 2007)
Axela Biosensors and Abnova to Co-Develop Biomarker Panels (Sep. 27, 2006)

Previous articleIntellectual Property at Crossroads
Next articleSanofi-Aventis Pays $140M Up Front in Cancer Deal with Exelixis